Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

Anita Turk, MD, details her biggest takeaways from the 2025 ASCO Annual Meeting in gastrointestinal cancers. Anita Turk, MD, medical oncologist at IU Health, discusses her biggest takeaways in the ...

Opdivo, which is used to treat certain types of cancer, can cause side effects such as confusion. Learn about Opdivo’s side effects and how to manage them.

Opdivo is used in adults to treat various cancers, including non-small cell lung cancer, melanoma, and classic Hodgkin’s lymphoma.For treating melanoma and a type of colorectal cancer, Opdivo ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for some types of cancer in adults and certain children. As with other drugs, Opdivo can cause side effects, such as joint pain and fatigue.

The Opdivo (nivolumab) market report provides a comprehensive analysis of the market's dynamics, focusing on size, growth potential, segmentation, and regional breakdown. Key factors driving ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

Opdivo (nivolumab) is a brand-name intravenous (IV) infusion prescribed for certain cancers. The cost of the drug, with and without insurance, can depend on several factors, such as whether Opdivo ...

U.S. Food and Drug Administration Approves Opdivo ® (nivolumab) plus Yervoy ® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma. Based on the Phase 3 ...

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its checkpoint inhibitors Opdivo and Yervoy, when combined, reduced ...

Opdivo (nivolumab) and Opdivo Qvantig (nivolumab/hyaluronidase-nvhy) are a type of cancer treatment called immunotherapy. Immunotherapy works by using the body's immune system to fight cancer ...

Opdivo vs. Keytruda. This month there was disappointment for Bristol-Myers Squibb which has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo into new ...